NXTC - NextCure, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
9.28
+0.36 (+4.04%)
As of 12:24PM EDT. Market open.
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close8.92
Open8.91
Bid9.25 x 800
Ask9.29 x 800
Day's Range8.69 - 9.32
52 Week Range8.00 - 109.00
Volume429,019
Avg. Volume765,211
Market Cap255.361M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.81
Earnings DateAug 10, 2020 - Aug 14, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est25.89
  • Scott+Scott Attorneys at Law LLP Announces Investigation into NextCure, Inc. (NXTC)
    PR Newswire

    Scott+Scott Attorneys at Law LLP Announces Investigation into NextCure, Inc. (NXTC)

    Scott+Scott Attorneys at Law LLP ("Scott+Scott"), an international shareholder and consumer rights litigation firm, is investigating whether NextCure, Inc. ("NextCure" or the "Company") (NASDAQ: NXTC) or certain of its officers and directors violated federal securities laws. If you purchased NextCure securities pursuant and/or traceable to NextCure's offering in November 2019 or have otherwise suffered a loss, realized or unrealized, you are encouraged to contact Scott+Scott attorney Jonathan Zimmerman at (888) 398-9312 for more information.

  • GlobeNewswire

    NextCure Provides an Interim Update of the Phase 2 Portion of the NC318 Monotherapy Phase 1/2 Trial and Announces Departure of Chief Medical Officer

    BELTSVILLE, Md., July 13, 2020 -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class.

  • GlobeNewswire

    NextCure Initiates Phase 1/2 Clinical Study of NC410, a Novel Immunomedicine, for Solid Tumors

    NextCure, Inc. (NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the initiation of a Phase 1/2 clinical trial for NC410, a novel immunomedicine developed to block immune suppression mediated by an immune modulator called LAIR-1. LAIR-2 is a naturally occurring soluble version of LAIR-1, which binds to and blocks the inhibitory activity of LAIR-1 and thus acts as a decoy protein.

  • NextCure, Inc. (NXTC): Are Hedge Funds Right About This Stock?
    Insider Monkey

    NextCure, Inc. (NXTC): Are Hedge Funds Right About This Stock?

    Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter. You can find articles about an individual hedge fund's trades on numerous financial […]

  • GlobeNewswire

    NextCure Presents Biomarker Data and Updated Clinical Results from Phase 1 Portion of its NC318 Clinical Trial at the 2020 Virtual American Society of Clinical Oncology Annual Meeting

    NextCure, Inc. (NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the presentation of biomarker data and updated clinical results from the Phase 1 portion of its ongoing Phase 1/2 monotherapy trial with NC318 at the 2020 Virtual American Society of Clinical Oncology (ASCO20) Annual Meeting. “Because this is a trial in progress with limited samples, we cannot draw definitive conclusions, but we believe these early biomarker data provide additional evidence of NC318 activity,” said Kevin N. Heller, M.D., NextCure’s chief medical officer.

  • 7 High-Risk Stocks For Market Gamblers
    Benzinga

    7 High-Risk Stocks For Market Gamblers

    Casinos are just starting to open back up following COVID-19 shutdowns, but it may still be a while before some gamblers are willing to venture back to Vegas or even their local casino. Sports gamblers are still waiting for the return of Major League Baseball and other pro and college sports leagues.In the meantime, some gamblers are looking to get their thrills in the stock market. But as many new traders learn the hard way, placing bets on the wrong stocks can be just as costly as picking the wrong horse at the racetrack.Here are eight Bank of America buy-rated stocks that have high volatility ratings and at least 40% upside to analyst price targets.Golar LNG (NASDAQ: GLNG) Golar LNG owns and operates one of the largest independent liquid natural gas carriers and floating storage fleets in the world.Analyst Ken Hoexter says Golar is a leader in the LNG transport and energy infrastructure business, and it has advantages over many of its competitors due to its more diversified offerings. In addition, Bank of America is bullish on long-term LNG prices as more terminals in Australia, Russia and the U.S. come online this year. Hoexter says there is upside to the company's Golar Power EBITDA over the next two years.Bank of America has a Buy rating and $15 price target for GLNG stock.Gossamer Bio Inc (NASDAQ: GOSS) Gossamer Bio is a biotech company with a pipeline of clinical and preclinical drug candidates focused on immunology, inflammation and oncology.Analyst Geoff Meacham said in March that Gossamer has several clinical candidates that have the potential to have massive total addressable markets treating a wide range of common conditions, including asthma and pulmonary arterial hypertension. Meacham said the company has a long list of potential near-term catalysts ahead that could potentially de-risk the stock and generate significant upside. He said data on BG001 in asthma is likely the biggest catalyst ahead.Bank of America has a Buy rating and $26 price target for GOSS stock.See Also: 7 Sin Stocks To Buy During The Coronavirus ShutdownLexinFintech Holdings Ltd - ADR (NASDAQ: LX) Lexin Fintech is an online consumer financing platform geared toward educated young adults in China.Analyst Eddie Lueng recently said he expects the company will shift gears from user growth in the second half of 2019 to optimizing its user acquisitions in the first half of 2020 due to the pandemic. Lueng says the company has a relatively sticky user base compared to its peers, and it's also exposed to less regulatory risk. Its user base of around 5 million people is only about 5% penetration of China's educated young adult demographic.Bank of America has a Buy rating and $19.80 price target for LX stock.Millicom International Cellular SA (NASDAQ: TIGO) Millicom is a telecom provider for nearly 50 million customers in Latin America and Africa.Analyst Rodrigo Villanueva recently said management took decisive action in preparing for the economic downturn by implementing more than $100 million in cost savings, cutting between $200 million and $300 million in capex, suspending $100 million in 2020 dividend payments and pausing $150 million in buybacks. Villanuava says prioritizing liquidity and cash is the right move, and the company's subscription-based revenue should prove relatively resilient during the downturn while the stock's valuation provides long-term upside.Bank of America has a Buy rating and $56 price target for TIGO stock.GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) GW Pharmaceuticals is a biopharmaceutical company that focuses primarily on developing cannabinoid-based drugs for a wide variety of applications. GW's Epidiolex was the first ever cannabis-based medication ever approved by the FDA.Analyst Tazeen Ahmad recently said Epidiolex's label could soon expand beyond epilepsy to tuberous sclerosis complex in the U.S., while launches in countries like Germany, the UK, France, Spain and Italy are also driving near-term revenue upside. Ahmad said Epidiolex's sales trajectory up to this point has been impressive and has closely tracked the results of Bank of America's previous doctor surveys.Bank of America has a Buy rating and $230 price target for GWPH stock.NextCure Inc (NASDAQ: NXTC) NextCure is a clinical stage biotech company developing cancer treatments.Analyst Alec Stranahan recently spoke to NextCure management following Bank of America's 2020 Healthcare Conference, and Stranahan said the COVID-19 outbreak has negatively impacted enrollment of the company's ongoing NC318 Phase II testing. In addition, studies of NC410 and NC318 have also been disrupted.Given the delays, Stranahan estimated the highly anticipated Phase II NC318 data will likely now come in the first half of 2021 rather than the fourth quarter of 2020. The massive potential of NC318 and NC410 created home run potential for investors, but the inherent risk in the early-stage trial data generates inherent risk.Bank of America has a Buy rating and $62 price target for NXTC stock.SINA Corp (NASDAQ: SINA) Sina is the owner of leading online social media and wireless value-added service Weibo in China.Leung recently said Sina's ad revenue took a significant hit in the first half of 2020, but the COVID-19 outbreak likely went a long way in highlighting the value of Weibo given the government and media outlets used it to disseminate information. Leung is calling for a 1% drop in revenue in 2020, including a 10% decline in portal ads and a 9% increase in fintech revenue.Like many other stocks, Leung is anticipating a strong recovery in the second half of the year and said user monetization, advertising, membership growth and app improvements are all bullish long-term drivers.Bank of America has a Buy rating and $57 price target for SINA stock.Latest Ratings for GWPH DateFirmActionFromTo May 2020Cantor FitzgeraldMaintainsOverweight Apr 2020Northland Capital MarketsInitiates Coverage OnOutperform Mar 2020CitigroupInitiates Coverage OnBuy View More Analyst Ratings for GWPH View the Latest Analyst Ratings See more from Benzinga * Cannabis Short Sellers Down 1M In May * Cannabis Stock Rally Puts Short Sellers In The Red For 2020(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • NextCure Inc (NXTC) Beats Q1 Earnings and Revenue Estimates
    Zacks

    NextCure Inc (NXTC) Beats Q1 Earnings and Revenue Estimates

    NextCure Inc (NXTC) delivered earnings and revenue surprises of 156.90% and 1621.39%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    NextCure Reports First Quarter 2020 Financial Results

    BELTSVILLE, Md., May 07, 2020 -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class.

  • GlobeNewswire

    NextCure to Present at BofA Securities Virtual Health Care Conference

    NextCure, Inc. (NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the BofA Securities Virtual Health Care Conference on May 13th at 9:00 am Eastern time. A live audio webcast will be available through the Investors section of the company’s website at www.nextcure.com. NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases.

  • Hedge Funds Have Never Been This Bullish On NextCure, Inc. (NXTC)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On NextCure, Inc. (NXTC)

    We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]

  • GlobeNewswire

    NextCure Provides Update on Clinical Trial Activities Due to Impact of COVID-19 Pandemic

    NextCure, Inc. (NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today provided an update on the company's clinical trial activities due to the impact of the COVID-19 pandemic. “The COVID-19 pandemic has put significant strain on our clinical trial sites, and has raised concerns around monitoring patient safety,” said Michael Richman, NextCure’s president and chief executive officer.

  • GlobeNewswire

    NextCure to Present at the 19th Annual Needham Virtual Healthcare Conference

    NextCure, Inc. (NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the 19th Annual Needham Virtual Healthcare Conference on April 15th at 2:10 pm Eastern time. A live audio webcast will be available through the Investors section of the company’s website at www.nextcure.com. NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases.

  • GlobeNewswire

    NextCure Announces Appointment of Veteran Oncology Executive Garry Nicholson to its Board of Directors

    NextCure, Inc. (NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appointment of Garry Nicholson to its board of directors. Mr. Nicholson has more than 30 years of product development and commercialization experience and previously held leadership positions at Pfizer Oncology and Eli Lilly and Company. In addition, Timothy M. Shannon, M.D. notified NextCure that he is stepping down from the company’s board of directors.

  • GlobeNewswire

    NextCure Reports Fourth Quarter and Full Year 2019 Financial Results

    BELTSVILLE, Md., March 12, 2020 -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class.

  • GlobeNewswire

    NextCure to Present at the 40th Annual Cowen Health Care Conference

    NextCure, Inc. (NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the 40th Annual Cowen Health Care Conference in Boston on March 4 at 8:00 am. A live audio webcast will be available through the Investors section of the company’s website at www.nextcure.com. NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases.

  • GlobeNewswire

    NextCure to Present at 9th Annual SVB Leerink Global Healthcare Conference

    NextCure, Inc. (NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the 9th Annual SVB Leerink Global Healthcare Conference in New York on February 25 at 9:00 am. A live audio webcast will be available through the Investors section of the company’s website at www.nextcure.com. NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases.

  • Eli Lilly ends deal with NextCure worth up to $1.4B for the local biotech
    American City Business Journals

    Eli Lilly ends deal with NextCure worth up to $1.4B for the local biotech

    Under the deal, inked in November 2018, NextCure gave Eli Lilly access to its proprietary platform for research aimed at developing and commercializing new cancer therapies.

  • GlobeNewswire

    NextCure to Present at the 38th Annual J.P. Morgan Healthcare Conference

    BELTSVILLE, Md., Jan. 06, 2020 -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class.

  • 3 Healthcare Stocks With 100% Street Support
    TipRanks

    3 Healthcare Stocks With 100% Street Support

    Getting everyone on board isn’t always easy. Whether out at a restaurant ordering a shared platter with friends, or choosing a song from a playlist, it can be challenging to reach an agreement with those around you, and mostly impossible to please everyone at the same time.Of course, there are exceptions to the rule, and even the analysts on Wall Street all reach the same conclusion at times. Common disagreements on whether a stock is over-sold or over-bought, are periodically put aside as a consensus is reached about one’s potential.The odds are even harder to beat when considering the future potential of stocks from the same sector, so when everyone is singing from the same hymn sheet, it’s time to take notice.With this in mind, we used TipRanks’ Analysts' Top Stocks tool to home in on 3 stocks in the same sector (healthcare in our case) which have received nothing but bullish shout outs in the last three months, and which, additionally, all have a Strong Buy consensus rating. Let’s get the lowdown.NextCure Inc (NXTC)This biotech, which develops new cancer drugs, has been turning heads on the Street recently.As is common in the sector, NextCure’s share price skyrocketed at the start of November following the release of promising data from early clinical trial results for its cancer treatment, NC318, an antibody targeting Siglec-15 (an immuno-suppressive protein of the tumor micro-environment). The news caused the share price to soar almost 250% in a single day. Roughly a week later, the stock crashed by over 50% in a session, following updated data which wasn’t quite as promising.These shenanigans are common in the volatile world of biotechs, and not much is to be deduced from the wild price swings following such early results. As it happens, in this case, NextCure’s pedigree is very strong.The company’s founder is Dr. Lieping Chen, Professor of Immunobiology at Yale University, and discoverer of the PD-L1/PD1 pathway, which showed that blocking the interaction between PD-1 and PD-L1 by monoclonal antibodies had a positive effect on the immune system’s ability to eliminate tumors.NextCure has other cancer treatment medicines in the pipeline, and BTIG’s Robert Hazlett sets out the bullish case for the recently listed biotech.The 5-star analyst noted, “NC318 has material promise as it modifies the activity of S15, a potent immunosuppressive protein, in the tumor microenvironment (TME). Normally S15 is expressed at very low levels, but in the TME, it is materially overexpressed, creating the potential for a meaninful immuno-oncology target, as it is present in 15-25% in NSCLC, TNBC, ovarian and head & neck cancers, providing NC318 with multi-billion dollar potential. NextCure is also employing its FIND-IO discovery platform toward developing other IO therapies.”Therefore, Hazlett initiated coverage on NextCure with a Buy rating, and set a price target of $61. As share prices surged at the end of last week, the upside potential comes in at a modest 4%. (To watch Hazlett’s track record, click here)Three other analysts tracked over the last 3 months all rate NextCure as a Buy, which collectively adds up to a Strong Buy consensus rating. The fellow analysts are even more bullish than Hazlett, as the average price target of $68.75 implies potential upside of 17%. (See NextCure stock analysis on TipRanks) Axsome Therapeutics Inc (AXSM)On to the Street’s next promising healthcare choice, and we encounter a recurring theme. Axsome therapeutics is up by over 115% in the last week, following -you guessed it- positive trial data.The CNS (central nervous system) focused biotech, released results for its experimental anti-depression drug, AXS-05, showing the treatment met the primary endpoint in a Phase 3 clinical trial. Axsome plans to submit an application to the FDA for approval of the therapy in the second half of 2020.The positive results back up a previous phase 2 trial in which AXS-05 exhibited superior efficacy compared to Bupropion for both MDD (major depressive disorder) and smoking cessation.BTIG’s Robert Hazlett also covers Axsome and reminds investors of the company’s potential. “Taken together, these data show consistent, rapid, durable, and significant anti-depressant effects of AXS-05 and de-risk AXS-05 in MDD; with additional strong results, we also modestly reduce our discount for AXS-05 in treatment resistant depression (TRD) as well… Given AXS-05’s relatively clear path to approval, consistent efficacy profile, and oral delivery, we now formally include M&A exit optionality into our valuation… We believe there is evidence that AXS-05’s broad activity at multiple CNS receptors (NMDA, Sigma-1, others) has the potential to support its use in multiple large CNS indications with peak sales potential of several billion dollars,” he said.Therefore, Hazlett reiterated his Buy recommendation on Axsome, alongside a price target of $97.A full house of 9 Buys bestows on Axsome Strong Buy status. As the average price target stands at $123.50, there is further room for growth in the shape of 23%. (See Axsome stock analysis on TipRanks) iRhythm Technologies (IRTC)Digital healthcare company, iRhythm Technologies, has had a poor 2019, with its share price losing 12% year-to-date. Looking at the bigger picture, though, the cardiac device specialist still has a lot going for it.The company’s flagship product, Zio, is a wearable patch that detects cardiac symptoms and has gained quick adoption due to ease of use and accurate data readings.iRhythm’s marketing strategy of getting a foot in the door at doctors’ offices to set up new accounts, has seen use of the Zio XT patch in diagnostic situations rise from 10% of accounts at the end of 2016 to 70% by 2018’s close. A further addition of sales representatives indicates the company will see out 2019 with as many as 140 sales reps, compared to 110 at the end of 2018, and significantly more than 2017’s 86.RBC’s Brandon Henry is with the bulls on iRhythm. The 4-star analyst noted, “We believe IRTC’s core business will continue to perform well, led by new sales rep adds, increased sales rep productivity, the full commercial launch of Zio AT (which should drive additional XT sales), and continued penetration in large integrated hospitals.”To this end, Henry reiterated an Outperform rating on the medical instrument maker, alongside a price target of $109. Should the target be met, gains of almost 79% could be in line over the next 12 months. (To watch Henry’s track record, click here)Where does the Street stand on iRhythm? The Street agrees with Henry. The cardiac device developer has a Strong Buy consensus rating, based on 3 Buy recommendations. The average target price adds 50 cents to the RBC analyst’s target and comes in at $109.50, implying handsome upside potential of 80%. (See iRhythm's price targets and analyst ratings on TipRanks)

  • Is NextCure, Inc. (NXTC) A Good Stock To Buy ?
    Insider Monkey

    Is NextCure, Inc. (NXTC) A Good Stock To Buy ?

    We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]

  • GlobeNewswire

    NextCure to Present at Piper Jaffray 31st Annual Healthcare Conference

    NextCure, Inc. (NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that the company will present at the Piper Jaffray 31st Annual Healthcare Conference in New York on December 3, 2019 at 2:00 pm ET. A live audio webcast will be available through the Investors section of the company’s website at www.nextcure.com. NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases.

  • GlobeNewswire

    NextCure Announces Closing of Public Offering

    BELTSVILLE, Md., Nov. 19, 2019 -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class.

  • GlobeNewswire

    NextCure Announces Pricing of Public Offering of Common Stock

    BELTSVILLE, Md., Nov. 14, 2019 -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class.

  • GlobeNewswire

    NextCure Announces Proposed Public Offering of Common Stock

    NextCure, Inc. (NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced a proposed public offering of 3,200,000 shares of its common stock. In addition, NextCure intends to grant the underwriters a 30-day option to purchase up to an additional 480,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the common stock to be sold in the offering will be offered by NextCure.

  • Benzinga

    Analyst Trims NextCure Price Target Following SITC Presentation, Still Sees Big Upside

    NextCure Inc (NASDAQ: NXTC) shares are settling down after the volatile run in the past few sessions. Alec Stranahan reiterated an Overweight rating price on NextCure and reduced the price target from $92 to $89. With the large unmet need for new immunotherapy approaches for cancer, the unique mechanism of action of NextCure's NC318 and NC410 is attractive, Stranahan said in a note.